Adaptation of Microarray Assay for Serum Amyloid a Analysis in Human Serum

Smoldovskaya, Olga; Voloshin, S A; Novikov, A A; Александрова, Е. Н.; Feyzkhanova, Guzel; Rubina, A. Yu.

doi:10.1134/s0026893322020145

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum amyloid A protein (SAA) is another inflammatory biomarker that is more sensitive than other acute-phase proteins, but with lower availability and higher cost [ 74 ]. The key role of SAA in different inflammatory rheumatic conditions including axSpA is its involvement in inflammasome cascade activation and recruitment of interleukin (IL)-17-producing T helper cells [ 75 ].…”

Section: Systemic Markers Of Inflammationmentioning

confidence: 99%

Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis

Diaconu

Ceasovschih

Șorodoc

et al. 2022

IJMS

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that can lead to ankylosis by secondary ossification of inflammatory lesions, with progressive disability and a significant impact on quality of life. It is also a risk factor for the occurrence of comorbidities, especially cardiovascular diseases (CVDs), mood disorders, osteoporosis, and malignancies. Early diagnosis and treatment are needed to prevent or decrease functional decline and to improve the patient’s prognosis. In respect of axSpA, there is an unmet need for biomarkers that can help to diagnose the disease, define disease activity and prognosis, and establish personalized treatment approaches. The aim of this review was to summarize the available information regarding the most promising biomarkers for axSpA. We classified and identified six core categories of biomarkers: (i) systemic markers of inflammation; (ii) molecules involved in bone homeostasis; (iii) HLA-B27 and newer genetic biomarkers; (iv) antibody-based biomarkers; (v) microbiome biomarkers; and (vi) miscellaneous biomarkers. Unfortunately, despite efforts to validate new biomarkers, few of them are used in clinical practice; however, we believe that these studies provide useful data that could aid in better disease management.

show abstract

Section: Systemic Markers Of Inflammationmentioning

confidence: 99%